NAD Peptide: Why NAD+ Is Not a Peptide at All

A peptide is two or more amino acids joined by peptide bonds. The bond is an amide link between the carboxyl group of one residue and the amino group of the next. GHK-Cu has 3 amino acids and 2 peptide bonds. BPC-157 has 15 residues and 14 peptide bonds. Semaglutide has 31 residues and 30 bonds.

NAD+ has none of that. Take it apart and you get two nucleotides bolted together through a pyrophosphate bridge. One half is nicotinamide mononucleotide: a nicotinamide ring, a ribose sugar, a phosphate. The other half is adenosine monophosphate: an adenine base, a ribose sugar, a phosphate. Two nucleotides, hence "di-nucleotide."

There is one amide group in NAD+, the carboxamide hanging off the nicotinamide ring. It links a carbon to a nitrogen. It does not join two amino acids to each other, which is the only thing that makes an amide bond a peptide bond. The count stands at zero.

Think of a coenzyme as a rechargeable battery pack that plugs into hundreds of different machines on a factory floor. It carries no instructions. It carries charge. NAD+ accepts two electrons and a proton at one enzyme, becomes NADH, hands the electrons off at the mitochondrial electron transport chain, and returns as NAD+ to do it again. Literally: NAD+ is a redox cofactor cycling between oxidized and reduced forms, and it also serves as a consumed substrate for sirtuins, PARPs, and CD38 in DNA repair, gene expression, calcium signalling, and immunoregulation (Braidy & Liu, Exp Gerontol, 2020).

Peptides do a different job entirely. They dock into receptors and change what a cell does next. MOTS-c is a 16-amino-acid mitochondrial peptide that alters metabolic signalling; Epitalon is a four-residue tetrapeptide. NAD+ carries no message. It carries electrons. Grouping it with peptides because both arrive in a vial is like filing motor oil under "spark plugs" because both go under the hood.

NAD+ weighs 663.4 g/mol and carries two phosphate groups that sit negatively charged at blood pH. Cell membranes are lipid bilayers. Large charged molecules do not drift across a lipid bilayer without a dedicated transporter, and no established plasma-membrane transporter for intact NAD+ has been identified in humans.

So what happens to the bag? One published human study infused NAD+ intravenously at 3 micromoles per minute for 6 hours, roughly 717 mg of NAD+ delivered over the session. Plasma NAD+ and its metabolites showed no change at all for the first 2 hours. The authors concluded that at that infusion rate NAD+ is "rapidly and completely removed from the plasma," with a metabolite profile consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity (Grant et al., Front Aging Neurosci, 2019).

Translation: the molecule gets cleaved in circulation before most of it reaches a cell. At the 6-hour mark the study detected increased urinary excretion of NAD+ itself and of methylnicotinamide. Part of what you paid for leaves in your urine intact.

That study measured where the molecule went. It did not measure whether anyone felt better, thought more clearly, or aged more slowly. Those endpoints have not been tested against placebo in an injected-NAD+ trial. Anyone quoting Grant 2019 as evidence that IV NAD+ works has read the title and not the abstract.

Precursors sidestep the membrane problem by being smaller and, in the case of nicotinamide riboside, uncharged. Blood NAD+ rose as much as 2.7-fold after a single oral dose of NR in a pilot report on one individual, and doses of 100, 300, and 1,000 mg produced dose-dependent increases in the blood NAD+ metabolome in the first human pharmacokinetic trial (Trammell et al., Nat Commun, 2016). Small molecule, oral route, measurable biomarker. That is the whole trick.

Scenario 1: You buy a 12-month IV protocol.

Clinic pricing in 2026 clusters around $299 for a 250 mg drip, $399 for 500 mg, and $599 for 1,000 mg, with the full national range running $250 to $1,500 per session. A standard "loading then maintenance" protocol is 8 infusions of 1,000 mg across 4 weeks, then monthly top-ups.

Run the arithmetic. Loading: 8 x $599 = $4,792. Maintenance: 11 x $599 = $6,589. Year one total: $11,381. Sessions run 90 to 180 minutes each because the drip has to be slowed to keep the burning and chest tightness tolerable, so you also spend roughly 30 hours in a chair.

Oral NR at 1,000 mg/day costs about $50 a month, near $600 a year. The IV protocol costs 19 times more than the precursor that has the randomized controlled trials. The fix: price the protocol in the peptide cost calculator before you sign, then ask the clinic to name one placebo-controlled trial showing injected NAD+ improves a clinical outcome. There is not one. Benchmark the number against our how much do peptides cost breakdown, where a year of most protocols lands under $2,000.

Scenario 2: You accept a citation that swapped four variables.

A clinic hands you the Science 2021 paper as proof. That trial gave 250 mg/day of oral NMN for 10 weeks to postmenopausal women with prediabetes who were overweight or obese, and measured insulin-stimulated glucose disposal with a hyperinsulinemic-euglycemic clamp. Muscle insulin sensitivity and muscle insulin signalling increased (Yoshino M et al., Science, 2021).

To get from that result to "a 1,000 mg IV NAD+ drip will give you energy," you have to substitute the molecule (NMN becomes NAD+), the route (oral becomes intravenous), the population (prediabetic postmenopausal women become you), and the endpoint (a glucose clamp becomes a feeling). Four substitutions. Any one of them alone breaks the inference.

The counterweight is published too. Forty obese, insulin-resistant men took 2,000 mg/day of NR for 12 weeks and showed no improvement in insulin sensitivity, endogenous glucose production, glucose disposal, resting energy expenditure, lipolysis, or body composition (Dollerup et al., Am J Clin Nutr, 2018). Twelve aged men took 1 g/day of NR for 21 days: the muscle NAD+ metabolome rose and circulating inflammatory cytokines fell, while mitochondrial bioenergetics did not change (Elhassan et al., Cell Rep, 2019).

Raising the biomarker is settled. Changing how you feel is not. The fix: before you pay, ask two questions. Which endpoint did the study measure? Is the molecule in the syringe the molecule in the paper? A clinic that cannot answer both in one sentence is selling the citation, not the compound.

Four checks, in order. Each takes under ten seconds and none require a chemistry degree.

1. Look for a residue count or a sequence. Peptides get defined by their amino acids. Vendors list them: "pentadecapeptide," "tripeptide-1," "31 amino acids." NAD+ never carries a residue count because it has no residues. If the label says "dinucleotide," "mononucleotide," or "riboside," you are in nucleotide chemistry.

2. Read the molecular formula for phosphorus. Peptides are built from carbon, hydrogen, nitrogen, oxygen, and sometimes sulfur. They do not carry phosphorus in the backbone. The P2 at the end of C21H27N7O14P2 is the pyrophosphate bridge holding the two nucleotides together. Phosphorus in the backbone is a coenzyme or nucleotide tell.

3. Check the suffix. Names ending in -tide, -relin, or -morelin (semaglutide, sermorelin, ipamorelin) are peptides by naming convention. Names ending in -riboside, -mononucleotide, or -dinucleotide are not.

4. Divide the molecular weight by 110. Amino acid residues average roughly 110 daltons. NAD+ at 663.4 g/mol would work out to about 6 residues if it were a peptide. Ask the vendor to name those six. They cannot, because there are none.

What "NAD+ therapy" actually delivers. Once the infusion starts, extracellular enzymes cleave NAD+ into nicotinamide, NMN, and ADP-ribose, and the liver methylates nicotinamide into methylnicotinamide. Those are the species Grant and colleagues measured appearing in plasma and urine. You are paying clinic rates for a slow, parenteral, partially excreted route to nicotinamide, which is over-the-counter vitamin B3.

That distinction matters when you plan a stack. A coenzyme and a receptor-binding peptide do not interact the way two peptides do. Read the peptide stacking guide before mixing NAD+ with 5-Amino-1MQ, which raises intracellular NAD+ by inhibiting the NNMT enzyme rather than by supplying substrate from outside the cell.

Five molecules get sold under the same longevity banner. Only two of them have randomized controlled trials measuring anything past a blood level, and neither of those two is injected NAD+.

What the human evidence supports, stated precisely. Oral NR at 1,000 mg/day for 6 weeks was well tolerated and stimulated NAD+ metabolism in healthy middle-aged and older adults, with the authors calling for future trials on blood pressure and arterial stiffness rather than claiming the effect (Martens et al., Nat Commun, 2018). Oral NMN at 250 mg/day for 12 weeks in 60 older adults raised blood NAD+, shortened 4-metre walking time, and improved sleep quality scores, while missing its primary endpoint on a stepping test (Morifuji et al., Geroscience, 2024).

A systematic review of the field screened 1,545 articles and included 147, of which only 34 were clinical. Most of the favourable signal came from NAM, NR, and NMN, with NAD+ and NADH themselves contributing "to a lesser extent" (Braidy & Liu, Exp Gerontol, 2020). The molecule with the loudest marketing has the quietest evidence base.

If your goal is energy rather than a specific molecule, the MOTS-c dosage protocol at least deals in a receptor-level mechanism with published human dosing. Mitochondrial function has more than one lever, and NAD+ substrate supply is the one with the thinnest injectable evidence.

Mistake 1: Ordering "NAD peptide" from a research chemical vendor. No such molecule exists. What arrives is NAD+ disodium salt, NMN powder, or NR chloride, priced as if it were exotic. The fix: open the certificate of analysis and read the formula line. C21H27N7O14P2 is NAD+. Anything with a residue sequence is a peptide. Vet the source using where to buy peptides in 2026 before ordering.

Mistake 2: Stacking NAD+ with three real peptides and crediting NAD+. You start IV NAD+, BPC-157, and a growth hormone secretagogue in the same week, feel better, and re-book the drip at $599. Four variables changed and you attributed the result to the most expensive one. The fix: change one variable at a time, hold it for 4 weeks, log the outcome. Screen combinations in the peptide interaction checker first.

Mistake 3: Reading "raised blood NAD+" as "reversed aging." A 2.7-fold rise in blood NAD+ is a pharmacokinetic result, and every trial above that measured a biomarker also failed to demonstrate a matching functional outcome, except the two small studies noted in the table. Blood NAD+ is what got measured. Aging is what got advertised. The fix: separate biomarker studies from outcome studies whenever you evaluate a longevity claim, the same discipline applied in our SLU-PP-332 analysis.

Mistake 4: Switching to subcutaneous NAD+ because it is cheaper. Same molecule, same 663.4 g/mol, same two negative charges, same extracellular cleavage before it reaches a cell. The only thing that changed is the price and the injection site burn. No controlled efficacy trial supports either route. The fix: if the goal is raising NAD+, oral precursors have the trial data at roughly 5% of the cost. Review peptide therapy side effects before you inject anything, coenzyme or otherwise.